ClinicalTrials.gg
CompletedNCT02969369Updated Jul 5, 2024Results posted

A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

A Phase 2 interventional study of SEP-363856 and Placebo capsule in Parkinson Disease Psychosis, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 24 sites in United States. Open to participants aged 55 Years to 105 Years. Per ClinicalTrials.gov, last updated 2024-07-05.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
55 Years to 105 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Parkinson Disease by Otsuka Holdings Co., Ltd. — none open to participants now, none under way, none of them phase 3. Parkinson Disease · Otsuka Holdings Co., Ltd..

Enrollment
10th of 11
39 · median 143
Started
2016
the only one that year
Phase 2
5 of 12
none open now
Registered
12th of 12
by date

Among the 12 studies in Parkinson Disease by Otsuka Holdings Co., Ltd., this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2016, is one of 5 in phase 2, and was the 12th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 12 studies in Parkinson Disease by Otsuka Holdings Co., Ltd. is open now. The open studies under Parkinson Disease, anywhere →

Where they have run

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 55 Years to 105 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Parkinson Disease by Otsuka Holdings Co., Ltd. as a file.
02

Study summary

A study to evaluate the safety and tolerability of SEP-363856 in subjects with Parkinson's Disease Psychosis. This study is accepting male and female participants 55 years of age and older who have been diagnosed with Parkinson's Disease. This study will be conducted in 24 study centers in the United States.

The study will last approximately 21 weeks.

Read the detailed description

This is a multicenter, randomized, parallel-group, placebo-controlled study evaluating the efficacy, safety, and tolerability of double-blind SEP-363856 flexibly dosed at 25, 50, or 75 mg/day for 6 weeks followed by 12 weeks of open-label extension of SEP-363856 flexibly-dosed at 25, 50, or 75 mg/day in male and female subjects ≥ 55 years of age with a clinical diagnosis of PDP. The study will randomize approximately 36 subjects to 2 treatment groups in a 2:1 ratio (approximately 24 subjects to SEP-363856 and 12 to placebo). The study will consist of 4 periods: Screening/Washout Period (up to 14 days prior to Double-blind Treatment), Double-blind Treatment Period (6 weeks), Open-label SEP-363856 Treatment Period (12 weeks), and Follow-up Period (1 week after last dose) as shown in the following figure. All postBaseline clinic visits will have a window of ± 2 days relative to the date of the Baseline visit (Visit 3).

03

Conditions studied

  • Parkinson Disease Psychosis

Browse trials for

Keywords

  • Parkinson's Disease Psychosis
04

Who can participate

Ages eligible
55 Years to 105 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject, caregiver, and/or legally authorized representative understands and is willing to sign to participate in the study.
  • Subject must be willing and able to comply with the study procedures and visit schedules and must be able to follow verbal and written instructions.
  • Subject is male or female ≥ 55 years of age.
  • Subject meets established diagnostic criteria for Parkinson's disease of at least one year duration, consistent with the UK Brain Bank criteria
  • Subject has psychotic symptoms that began after the diagnosis of PD for at least one month, occurring at least weekly in the month prior to screening (according to subject or caregiver), and severe enough to warrant treatment with antipsychotics.
  • Subject has a combined score of at least 6 or an individual score of at least 4 on the neuropsychiatric inventory (NPI) Item A (delusions) and/or Item B (hallucinations). This crieterion must be met at Visit 1 and Visit 3.
  • Subject has a Mini-mental status examination () score > 21 points out of 30.
  • Subject has a caregiver (spouse or family member) who will be required to attend all visits and is able to provide study information on various scales such as the NPI.
  • Subject is taking antiparkinsonian drugs or deep brain stimulation, with a stable dose/dose regimen and settings for 3 months before enrolment.
  • Female subject must be postmenopausal defined as being amenorrheic for greater than two years with an appropriate clinical profile.
  • Male subjects with female partner(s) of must agree to avoid fathering a child and use acceptable methods of from screening until at least 30 days after the last study drug administration.
  • Subject is, in the opinion of the Investigator, medically stable based on screening medical history, PE, neurological examination, vital signs, clinical laboratory values (hematology, serum chemistry, urinalysis, lipid panel, coagulation panel, thyroid panel, and serum prolactin).
  • Subject has had a stable living arrangement at the time of screening.

Exclusion criteria

Exclusion Criteria:

  • Subject has psychosis secondary to other toxic or metabolic disorders.
  • Subject has atypical Parkinson's disease, Parkinsonism secondary to medication or other neurodegenerative disorders, such as progressive supranuclear palsy or multiple system atrophy.
  • Subject has dementia diagnosed concurrent with or before Parkinson's disease, motor symptoms that began less than one year before the onset of dementia or symptoms consistent with the diagnosis of lewy body dementia (LBD), or if the psychosis occurred after ablative stereotaxic surgery.
  • Subject failed 2 or more antipsychotic agents given at adequate doses for at least 4 weeks within 1 year before screening.
  • Subject has had a stroke or other uncontrolled serious medical or neurological illness within 6 months of baseline.
  • Subject answers "yes" to "Suicidal Ideation" Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the C SSRS at Screening (ie, in the past one month), or baseline (ie, since last visit).
  • Subject does not tolerate venipuncture or has poor venous access that would cause difficulty for collecting blood samples.
  • Subject has participated in an drug study and received investigational drug within 30 days (or longer if the half-life is known to be ≥ 150 hours) prior to the screening visit, or who is currently participating in another clinical study. Subject has previously received SEP 363856.
  • Subject has any unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study:
  • Subject has hematological (including deep vein thrombosis) or bleeding disorder, renal, metabolic, endocrine, pulmonary, gastrointestinal, urological, cardiovascular, hepatic, neurologic, or allergic disease that is clinically significant or unstable (except for untreated, asymptomatic, seasonal allergies at time of dosing).
  • Subject has a history of cancer or significant neoplasm.
  • Subject has a disorder or history of a condition or previous gastrointestinal surgery (eg, cholecystectomy, vagotomy, bowel resection, or any surgical procedure) that may interfere with drug absorption, distribution, metabolism, excretion, gastrointestinal motility, or pH, or a clinically significant abnormality of the hepatic or renal system, or a history of malabsorption.
  • Subject has Alcohol or Substance Abuse Disorder (DSM 5 criteria). The only exceptions are caffeine or nicotine.
  • Subject has a clinically significant abnormal 12 lead that may jeopardize the subject's ability to complete the study or a screening 12 lead ECG demonstrating any one of the following: heart rate > 100 beats per minute, QRS > 120 ms, corrected for heart rate using Fridericia's formula (QTcF) > 450 ms (males), QTcF > 470 ms (females), or PR > 220 ms.
  • Subjects with known (HIV) seropositivity will be excluded.
  • Female subject who is pregnant or lactating.
  • Subject has a presence or history of a medically diagnosed, clinically significant psychiatric disorder.
  • Subject is at significant risk of harming him/herself or others according to the Investigator's judgment.
  • Subject has attempted suicide within 3 months prior to screening.
  • Subject has a history of allergic reaction or suspected sensitivity to any substance that is contained in the formulation.
  • Subject has any clinically significant abnormal laboratory values (hematology, serum chemistry, urinalysis, lipid panel, coagulation panel, thyroid panel, serum prolactin, and urine drug screen(Note: abnormal findings that may be clinically significant or of questionable significance will be discussed with the Medical Monitor prior to including subject).
  • Subjects with serum (ALT) or aspartate transaminase (AST) levels ≥ 3 times, serum blood urea nitrogen (BUN) or creatine ≥ 1.5 X the upper limit of the reference ranges provided by the central laboratory require retesting. If on retesting, the laboratory value remains equal to or above the , the subject will be excluded.
  • Subjects with a random (non-fasting) blood glucose at screening ≥ 200 mg/dL (11.1 mmol/L) and ≥ 6.5% will be excluded.
  • Subject has a prolactin concentration > 100 ng/mL at screening or has a history of pituitary adenoma.
  • Subject's is ≥ 30 mg/kg/m2.
  • Subject has experienced significant blood loss (≥ 473 mL) or donated blood within 60 days prior to first dose of study drug; has donated plasma within 72 hours prior to the first dose of study drug or intends to donate plasma or blood or undergo elective surgery during study participation or within 60 days after the last study visit.
  • Subject consumes more than 300 mg of caffeine per day (5 cups of coffee or equivalent in caffeinated beverages).
  • Subject has used disallowed prescription medications or anticipates the need for any disallowed medication during their participation in this study. Subject is a staff member or the relative of a staff member.
  • Subject is in the opinion of the Investigator, unsuitable in any other way to participate in this study.

Continuation into Open-label Extension Cirteria

  • Subject must have completed the 6-week double-blind treatment.
  • Subject has not taken any medication other than the study drug for the purpose of controlling PDD symptoms

    . • There has been no clinically significant change in the subject's medical condition or Parkinson's disease, in the opinion of the investigator.

  • Subject has not answered "yes" to "suicidal ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at any time during the DB treatment period.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    SEP-363856

    SEP-363856 (25, 50, or 75mg/day), once daily

    Drug: SEP-363856

  • Placebo comparator
    Placebo Capsule

    Placebo once daily

    Drug: Placebo capsule

Interventions

  • SEP-363856 (25, 50, or 75mg/day)

  • DrugPlacebo capsule

    Placebo once daily

06

What researchers measure

Primary outcomes

  1. Change From Double Blind (DB) Baseline in Total Scale for Assessment of Positive Symptoms - Parkinson's Disease ( SAPS-PD) Score at Week 6

    There are seven items assessing individual symptoms (four items for hallucinations and three items for delusions), a global hallucinations item and a global delusions item. Separate items are rated from 0 (absent) to 5 (severe), so that higher values represent a worse outcome. Total score is equal to the sum of the seven items plus the global hallucinations, plus the global delusions. Therefore a total possible score on the SAPS-PD ranges from 0 to 45. The primary analysis of the primary efficacy variable will use a mixed model for repeated measures (MMRM).

    Time frame: SAPS-PD assessments during DB treatment period, Baseline and Week 6

Secondary outcomes

  1. Change From Double Blind (DB) Baseline in the Clinical Global Impression-Severity of Illness (CGI-S) at Week 6.

    The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity. Analysis Method: Mixed Model Repeated Measures (MMRM)

    Time frame: CGI-S assessments during DB treatment period, Baseline and Week 6

  2. Change From Double Blind (DB) Baseline in Neuropsychiatric Inventory (NPI) at Week 6

    The NPI is a 12-item behavior rating scale composed of a structured interview of the caregiver, which assesses psychiatric disturbance. For each subdomain, both the frequency (0 to 3 scale) and the severity (0 to 4 scale) of symptoms is determined. Higher scores represent a worse outcome. The subdomain score is the product of these two measures and ranges from 0 to 12. The combined NPI score is obtained by summing all 12 sub-domain scores and therefore ranges from 0 to 144. Analysis Method: Mixed Model Repeated Measures (MMRM)

    Time frame: NPI assessments during DB treatment period, Baseline and Week 6

  3. Change From Double-blind (DB) Baseline in Mini Mental State Evaluation (MMSE) at Week 6

    The Mini Mental State Examination (MMSE) for Cognition is a brief instrument, used to assess cognitive function, consisting of 11 tests including orientation, memory (recent and immediate), concentration, language, and praxis. Scores range from 0 to 30, with lower scores indicating greater cognitive impairment. MMSE, the total score is the sum of all 11 tests. Analysis Method: Mixed Model Repeated Measures (MMRM)

    Time frame: MMSE assessments during DB treatment period, Baseline and Week 6

07

Results

Posted Jun 5, 2023

Participant flow

Study
Participant flow — Study
MilestonePlaceboSEP-363856
Started1425
Modified intent-to-treat population1424
Completed1011
Not completed414
Withdrew: Adverse event16
Withdrew: Lack of efficacy01
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject35
Withdrew: Withdrawal by pi due to other underlying illnesses01
Double-blind Period
Participant flow — Double-blind Period
MilestonePlaceboSEP-363856
Started1425
Modified intent-to-treat population1424
Completed1115
Not completed310
Withdrew: Adverse event15
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject23
Withdrew: Withdrawal by pi due to other underlying illnesses01
Open-label SEP-363856 Period
Participant flow — Open-label SEP-363856 Period
MilestonePlaceboSEP-363856
Started79
Completed65
Not completed14
Withdrew: Adverse event01
Withdrew: Lack of efficacy01
Withdrew: Withdrawal by subject12

Outcome measures

PrimaryChange From Double Blind (DB) Baseline in Total Scale for Assessment of Positive Symptoms - Parkinson's Disease ( SAPS-PD) Score at Week 6

There are seven items assessing individual symptoms (four items for hallucinations and three items for delusions), a global hallucinations item and a global delusions item. Separate items are rated from 0 (absent) to 5 (severe), so that higher values represent a worse outcome. Total score is equal to the sum of the seven items plus the global hallucinations, plus the global delusions. Therefore a total possible score on the SAPS-PD ranges from 0 to 45. The primary analysis of the primary efficacy variable will use a mixed model for repeated measures (MMRM).

Time frame:
SAPS-PD assessments during DB treatment period, Baseline and Week 6
Reported as:
Least squares mean · Units on a scale
Change From Double Blind (DB) Baseline in Total Scale for Assessment of Positive Symptoms - Parkinson's Disease ( SAPS-PD) Score at Week 6
Units on a scalePlaceboSEP-363856
Change From Double Blind (DB) Baseline in Total Scale for Assessment of Positive Symptoms - Parkinson's Disease ( SAPS-PD) Score at Week 6-1.4 (-5.6 to 2.8)-2.5 (-5.8 to 0.8)
SecondaryChange From Double Blind (DB) Baseline in the Clinical Global Impression-Severity of Illness (CGI-S) at Week 6.

The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity. Analysis Method: Mixed Model Repeated Measures (MMRM)

Time frame:
CGI-S assessments during DB treatment period, Baseline and Week 6
Reported as:
Least squares mean · Units on a scale
Change From Double Blind (DB) Baseline in the Clinical Global Impression-Severity of Illness (CGI-S) at Week 6.
Units on a scalePlaceboSEP-363856
Change From Double Blind (DB) Baseline in the Clinical Global Impression-Severity of Illness (CGI-S) at Week 6.-0.7 (-1.5 to 0.1)-0.4 (-1.1 to 0.3)
SecondaryChange From Double Blind (DB) Baseline in Neuropsychiatric Inventory (NPI) at Week 6

The NPI is a 12-item behavior rating scale composed of a structured interview of the caregiver, which assesses psychiatric disturbance. For each subdomain, both the frequency (0 to 3 scale) and the severity (0 to 4 scale) of symptoms is determined. Higher scores represent a worse outcome. The subdomain score is the product of these two measures and ranges from 0 to 12. The combined NPI score is obtained by summing all 12 sub-domain scores and therefore ranges from 0 to 144. Analysis Method: Mixed Model Repeated Measures (MMRM)

Time frame:
NPI assessments during DB treatment period, Baseline and Week 6
Reported as:
Least squares mean · Units on a scale
Change From Double Blind (DB) Baseline in Neuropsychiatric Inventory (NPI) at Week 6
Units on a scalePlaceboSEP-363856
Change From Double Blind (DB) Baseline in Neuropsychiatric Inventory (NPI) at Week 6-17.3 (-28.3 to -6.2)-11.5 (-20.2 to -2.8)
SecondaryChange From Double-blind (DB) Baseline in Mini Mental State Evaluation (MMSE) at Week 6

The Mini Mental State Examination (MMSE) for Cognition is a brief instrument, used to assess cognitive function, consisting of 11 tests including orientation, memory (recent and immediate), concentration, language, and praxis. Scores range from 0 to 30, with lower scores indicating greater cognitive impairment. MMSE, the total score is the sum of all 11 tests. Analysis Method: Mixed Model Repeated Measures (MMRM)

Time frame:
MMSE assessments during DB treatment period, Baseline and Week 6
Reported as:
Least squares mean · Units on a scale
Change From Double-blind (DB) Baseline in Mini Mental State Evaluation (MMSE) at Week 6
Units on a scalePlaceboSEP-363856
Change From Double-blind (DB) Baseline in Mini Mental State Evaluation (MMSE) at Week 60.3 (-0.9 to 1.4)-0.8 (-1.7 to 0.2)

Adverse events

Collected over All adverse events (AEs) during the 6-week DB and 12-week OL periods by actual treatment group.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/14 (0%)0/14 (0%)12/14 (85.7%)
SEP-3638560/32 (0%)2/32 (6.3%)22/32 (68.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboSEP-363856
Hip fractureInjury, poisoning and procedural complications0/141/32
Mental disorderPsychiatric disorders0/141/32
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPlaceboSEP-363856
HallucinationPsychiatric disorders2/147/32
FallInjury, poisoning and procedural complications3/146/32
DizzinessNervous system disorders1/146/32
Confusional statePsychiatric disorders2/145/32
FatigueGeneral disorders2/142/32
HypertensionVascular disorders2/142/32
NauseaGastrointestinal disorders1/144/32
SomnolenceNervous system disorders0/143/32
AnxietyPsychiatric disorders0/143/32
DelusionPsychiatric disorders0/143/32

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboSEP-363856Total
<=18 years000
Between 18 and 65 years257
>=65 years122032
Age, Continuous
Age, Continuous(Years)PlaceboSEP-363856Total
Mean71.8 ± 7.1270.4 ± 7.3170.9 ± 7.18
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSEP-363856Total
Female145
Male132134
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboSEP-363856Total
Hispanic or Latino314
Not Hispanic or Latino112435
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboSEP-363856Total
Native Hawaiian or other Pacific Islander101
White122436
Asian011
Other101
Age, Customized
Age, Customized(Participants)PlaceboSEP-363856Total
>=55 - <65 years257
>=65 - <75 years71219
>=75 years5813
Baseline Body Mass Index (BMI) (kg/m^2)
Baseline Body Mass Index (BMI) (kg/m^2)(kg/m^2)PlaceboSEP-363856Total
Mean24.15 ± 5.23926.08 ± 4.80825.42 ± 4.975
Baseline Body Mass Index (BMI) Category
Baseline Body Mass Index (BMI) Category(Participants)PlaceboSEP-363856Total
<18.5 kg/m^2112
>=18.5 - <25.0 kg/m^27815
>=25.0 - <30.0 kg/m^231417
>=30.0 kg/m^2224
Missing101

3 further baseline measures are reported on the registry.

08

Study locations

24 sites
  • Neuuro-Pain Medical Center
    Fresno, California 93710, United States
  • Keck School of Medicine of USC/ University of Southern California
    Los Angeles, California 90033, United States
  • CiTrials
    Riverside, California 92521, United States
  • Georgetown University Hospial, Research Pharmacy Servcies
    Washington, District of Columbia 20007, United States
  • JEM Research Institute
    Atlantis, Florida 33462, United States
  • UHealth at Boca Raton
    Boca Raton, Florida 33431, United States
  • Parkinson's Disease and Movement Disorders Center of Boca Raton
    Boca Raton, Florida 33486, United States
  • University of Miami, Dept. of Neurology
    Miami, Florida 33136, United States
  • Compass Research
    Orlando, Florida 32802, United States
  • Neurology Associates of Ormond Beach
    Ormond Beach, Florida 32174, United States
  • Parkinson's Disease Treatment Center of Southwest Florida
    Port Charlotte, Florida 33980, United States
  • Suncoast Neuroscience Associates, Inc.
    Saint Petersburg, Florida 33713, United States
  • University of Florida Parkinson's Disease and Movement Disorder's Center
    Tampa, Florida 33613, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Henry Ford West Bloomfield Hospital
    West Bloomfield, Michigan 48322, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Brian Maddux
    Cincinnati, Ohio 45212, United States
  • The Movement Disorder Clinic of Oklahoma
    Tulsa, Oklahoma 74136, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • University of Pennsylvania, Department of Neurology
    Philadelphia, Pennsylvania 19107, United States
  • Inland Northwest Research
    Spokane, Washington 99202, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Apr 2020, 39 months.

Results were first posted in Jun 2023, 3 years 1 month after primary completion. A results delay was requested in Apr 2021.

Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 39 months is above that.

Counting every sponsor, half of 202 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2016
First posted
Nov 21, 2016
StartActual
Dec 31, 2016
Primary completionActual
Apr 20, 2020
CompletionActual
Apr 20, 2020
Results delay requested
Apr 12, 2021
Results first posted
Jun 5, 2023
Last update
Jul 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02969369
Responsible party
Sponsor
First posted
Nov 21, 2016
Start date
Dec 31, 2016
Primary completion
Apr 20, 2020
Completion
Apr 20, 2020
Results posted
Jun 5, 2023
Last update
Jul 5, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SEP-363856

Start the discussion